The translational potential of research on the ethical, legal and social implications of genomics by Burke, Wylie et al.
The Translational Potential of Research on the Ethical, Legal and 
Social Implications of Genomics
Wylie Burke1, Paul Appelbaum2, Lauren Dame3, Patricia Marshall4, Nancy Press5, Reed 
Pyeritz6, Richard Sharp7, and Eric Juengst8
Wylie Burke: wburke@u.washington.edu
1University of Washington, Seattle, WA
2Columbia University, New York, NY
3Duke University, Durham. NC
4Case Western University, Cleveland, OH
5Oregon Health and Science University, Portland, OR
6University of Pennsylvania, Philadelphia, PA
7Mayo Medical School, Rochester, MN
8University of North Carolina, Chapel Hill, NC
Abstract
Federally funded research on the ethical, legal and social implications of genomics (“ELSI” 
research) includes a programmatic charge to consider policy-relevant questions and to 
communicate findings in venues that help inform the policy-making process. In addressing this 
goal, investigators must consider the range of policies that are relevant to human genetics, how 
foundational research in bioethics, law, and the social sciences might inform those policies, and 
the potential professional issues that this translational imperative raises for ELSI investigators. We 
review these questions in the light of experiences from a consortium of federally funded Centers 
of Excellence in ELSI Research, and offer a set of policy recommendations for program design 
and evaluation of ELSI research. We conclude that it would be a mistake to require that ELSI 
research programs demonstrate a direct impact on science or health policy; however, ELSI 
researchers can take steps to increase the relevance of their work to policy makers. Similarly, 
funders of ELSI research concerned to facilitate policy development can help by building cross-
disciplinary translational research capacities, and universities can take steps to make policy-
relevant research more rewarding for scholars in the humanities, social sciences, and law.
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When the U.S. Human Genome Project was initiated in 1990, one of its innovative 
components was the Ethical, Legal and Social Implications (ELSI) Research Program (1). 
Initially a joint effort involving the U.S. Department of Energy and National Institutes of 
Health (NIH), the ELSI Research Program, now administered by the National Human 
Genome Research Institute (NHGRI), has supported a diverse portfolio of research grants 
and training awards. Although these research projects span multiple fields and employ a 
range of methods, they share the aim of examining the societal implications of genomic 
research and the medical innovations that it may make possible.
“ELSI research,” as it is commonly known, incorporates a wide range of disciplinary 
perspectives, including bioethics, history, law, medicine, genetics, economics, philosophy 
and the behavioral and social sciences. Unlike related work supported by other federal 
agencies such as the National Endowment for the Humanities or the National Science 
Foundation, a common challenge for ELSI research has been a programmatic charge to 
consider policy-relevant questions and to communicate its findings in venues that help 
inform the policy-making process. Just as basic genomic scientists are encouraged to pursue 
“translational” research that enables the creation of medically useful tools, ELSI researchers 
have a “translational” mandate to pursue studies that assist in managing practical policy 
problems involving human genomics (2).
Historically, criticism of the ELSI program has focused on its capacity to meet this practical 
challenge (e.g., 3). The challenge is particularly important for the consortium of Centers of 
Excellence in ELSI Research (CEER) established in 2004. The CEER consortium was 
created by the NHGRI with an explicit imperative to “play a role in ensuring that relevant 
ELSI research findings and deliberations are made available to policy makers as 
appropriate” (2).In addressing this goal, CEER investigators have had to consider the range 
of policies that are relevant to human genetics, how foundational research might inform 
those policies, and the potential professional issues that this translational imperative raises 
for ELSI investigators. We review these questions in the light of the CEER consortium's 
experiences to date, and offer a set of recommendations for clarifying the goals and 
strengthening the translational impact of policy-related ELSI research. We suggest that it 
would be a mistake to require that ELSI research programs demonstrate a direct impact on 
science or health policy; however, ELSI researchers can take steps to increase the relevance 
of their work to policy makers. Similarly, funders of ELSI research concerned with policy 
translation can foster cross-disciplinary translational capacities, and universities can take 
steps to make policy-relevant research more rewarding for scholars in the humanities, social 
sciences, and law. In making these recommendations, we hope to stimulate discussion aimed 
at developing consensus about how best to achieve the policy impact envisioned for the 
ELSI program.
What constitutes policy?
As ELSI researchers consider policy-relevant research, they must first decide how to define 
“policy.” Many definitions focus on governmental action, e.g., “the expressed intent of 
government to allocate resources and capacities to resolve [an] expressly identified issue 
within a certain timeframe” (4). Governmental policy-making at both state and federal levels 
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has important implications for genomic research and health care. Some policies are specific 
to clinical and public health applications of human genetics, such as state newborn screening 
programs and licensure for genetic counselors, and laws protecting against genetic 
discrimination (e.g., 5). Other governmental policies are more general, but have important 
implications for human genetics. Examples include federal regulations governing research 
with human participants (6); National Institutes of Health (NIH) policies on data-sharing and 
funding priorities (7); policies related to intellectual property and patenting; the Clinical 
Laboratory Improvement Amendments (CLIA) (8); and Federal Drug Administration (FDA) 
regulations regarding oversight of clinical tests (9).
However, policy actions with important implications for translational genomic research 
occur in other venues as well. Clinical practice guidelines, for example, help to set standards 
of care for the use of genomic technologies in health care. Guidelines are frequently 
sponsored by professional societies or other non-profit organizations; some, such as the 
Working Group for Evaluating Genomic Applications in Prevention and Practice (EGAPP) 
(10) and the U.S. Preventive Services Task Force (USPSTF) (e.g., 11), are independent 
panels sponsored by governmental agencies. Both the American College of Medical 
Genetics and Genomics (12) and the American College of Obstetrics and Gynecology (13) 
have played leading roles in development of clinical practice guidelines for genetic testing. 
The American Society of Human Genetics (14) and other organizations have considered 
policies related to genetic testing that are within their area of focus, including guidelines and 
advisory statements from the American Academy of Pediatrics (15) and the American 
Medical Association (e.g., 16).
At the local level, research and health care institutions and individual laboratories and 
clinics also develop and implement policies that influence the conduct of genomic research 
and its clinical translation. Frequently these are attempts to implement broader national and 
professional guidelines. In these processes, institutions play a role analogous to the 
“laboratory of the states” in federal policy-making, by providing experience-based 
assessments of alternative policy options and interpretations. Local experimentation has 
been particularly influential in the development of IRB policies for genomic research, 
informed consent practices, community engagement policies, and biobank governance 
(17-20).
There are also important forms of policy development that are rarely codified in particular 
documents or by specific organizations. At the societal level, for example, investment in 
genomic science, including allocation of research funding and capital investment can have 
an important impact on genomic research and its translation (21). Initiatives on the part of 
federal funding agencies, such as NHGRI's launch of a research program to assess outcomes 
of genomic sequencing in health care (22), contribute significantly to the evidence available 
to policymakers. Pharmaceutical companies, biotechnology industries, and private investors 
all influence how genome science will be moved from the laboratory to potential health 
applications. Health payers, by deciding what tests and procedures they reimburse, and at 
what level, influence both investment decisions and the potential for clinical 
implementation, thereby influencing the translational process.
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The evolving unwritten norms of clinical practice and the background social narratives that 
inform patient, family and public decision-making about the use of genomic information are 
also important in directing genomic translation. For example, The DNA Mystique: the Gene 
as a Cultural Icon (23), a widely cited qualitative media study of public understanding of 
genomic concepts, set the stage for policy concerns about genetic determinism and 
discrimination. As that work showed, background cultural influences are relatively invisible 
in the distilled language of official policy documents at the governmental or professional 
society levels, but are critically important to analyze as key moral commitments, beliefs, and 
practices that shape the reception of genomic technologies by potential users.
These diverse forms of policy-making call for a definition of policy that is not limited to 
governmental action. Merriam-Webster suggests that policy can be defined as “a definite 
course or method of action selected from among alternatives and in light of given conditions 
to guide and determine present and future decisions” (24). This definition has the scope to 
include both informal and formal forces that set the course of genomic translation, and 
underscores the broad range of research studies that should be considered “policy-relevant.”
Recommendation #1
The translational mandate for ELSI research should be interpreted expansively, to include 
governmental and professional policy but also the broader social, economic, and cultural 
influences that shape public reception and use of genomic information.
Interrelatedness of policy actions
A second major observation from ELSI research experience is that policy-relevant research 
must take into account how multiple policy actions interact to influence a particular aspect 
of genomic research or healthcare. The following examples drawn from ELSI research serve 
to illustrate the complexity:
Data-sharing—Mechanisms for sharing population and clinical data that incorporate 
demographic, phenotypic, genomic, and health measures could expedite the translation of 
genomic research findings into applications to improve health care (25). NIH policies have 
required funded researchers to have data-sharing plans for more than a decade, and recent 
policies provide strong incentives for depositing genomic data in a federal repository (26). 
However, as ELSI research has shown, data-sharing decisions may also be affected by 
policies surrounding informed consent (27, 28), agreements researchers have implemented 
with communities where research is conducted (29), proprietary interests (30), and in the 
case of health data, by the Health Insurance Portability and Accountability Act's Privacy 
Rule (31), as well as any relevant state legislation. How research data are organized and 
stored, the extent to which measures are harmonized, and what constitutes “data” are also 
relevant for implementing effective policies for data sharing. Private policies, even at the 
level of individual laboratories, can therefore have an impact on how data sharing is 
implemented (32). Data repositories, once established, need policies for evaluating data 
requests and models for oversight and stewardship of data resources (19, 33-35), including 
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procedures that ensure informational privacy, accountability and appropriate information 
return to patients (36-40).
Genetic/Genomic testing—Clinical molecular genetic tests represent an important 
product of genomic research, and are projected to improve diagnostic capabilities and guide 
safe and effective drug therapy. Like data sharing in genomic research, the introduction of 
new genetic tests raises an array of policy questions related to both governmental and non-
governmental action. Central among these is the development of clinical practice guidelines 
addressing the standardization of testing technology and the appropriate use of different 
tests. ELSI research initiatives have helped inform such guidelines, (e.g., 41-47), and today, 
ELSI researchers are participating in major initiatives and debates surrounding the 
development of clinical standards for whole exome and whole genome sequencing (e.g., 
48-57).
All of these professional practice initiatives proceed in the context of other important policy 
questions for the laboratories that develop and provide the testing. It is still unclear what 
degree of federal regulatory oversight is appropriate for a laboratory-developed test (LDT) 
that is not marketed to other laboratories (21), when LDTs are used for medical diagnostic 
or predictive purposes. Moreover, policy decisions about the patentability of a gene or the 
scope of a genetic test's patent can affect whether or how researchers, clinicians, or patients 
can access new genetic discoveries (25).
Recommendation #2
ELSI research is uniquely positioned to assemble and assess the interaction of policies 
occurring under the broad definitional rubric laid out in this paper. Because few single 
research projects can span the whole spectrum of relevant policy spheres, opportunities 
should be sought or where possible created to pursue policy-relevant ELSI research through 
collaborations between studies addressing different levels of policy-making, rather than by 
individual research projects attempting to extrapolate policy implications in isolation.
How can ELSI research contribute?
ELSI research contributes in different ways at different phases of the policy-making process: 
Phase 1: identification of policy issues; Phase 2: development of policy options; and Phase 
3: evaluation of policy effects (Figure). This process is envisioned as iterative, because the 
evaluation of policy efforts typically will identify new policy concerns that require 
additional attention. Empirical evidence and conceptual clarification can be useful at every 
stage, defining problems for which policy action is needed, elucidating stakeholders' views 
of alternative solutions, and evaluating outcomes of different policy approaches. 
Justifications for different options must also be considered. Normative research offers an 
opportunity to explore ethical justifications for policies, or provide insights into the values at 
play. Similarly, legal research can illuminate the ways in which different legal theories may 
affect innovation, dissemination, and application of new genetic diagnostic and therapeutic 
techniques. ELSI research can also contribute conceptual frames for understanding the 
challenges of genomics, and for guiding both policy development and further research. The 
study of health economics can inform how markets will view the introduction of genomics 
Burke et al. Page 5






















into health care and public health, especially with the heightened focus on and expectations 
of “personalized” or “precision” medicine.
Drawing on their scholarly work, ELSI researchers also frequently contribute directly to the 
deliberations of policy-making bodies. Advisory bodies convened by the federal 
government, the Institute of Medicine, and other organizations considering issues related to 
genomics typically include representation from the ELSI community or testimony from 
ELSI researchers (e.g., 58-61). ELSI researchers usually participate in these policy activities 
as individual professionals, sometimes leading critics to discount their contributions as 
independent of their programmatic mandate to do policy-relevant research (62). However, 
participation of ELSI researchers in policy activities is an outcome of the creation of a 
robust community of scholars sparked by the NHGRI ELSI research program, whose work 
and resulting insights have policy relevance for genomics.
Recommendation #3
The full interdisciplinary range of ELSI research at the stages of policy issue identification, 
policy option development, and policy impact assessment should be considered forms of 
translational ELSI research. The contributions that individual ELSI researchers make to 
policy initiatives cannot be easily separated from the research programs these individuals 
direct and should be considered evidence of the translational impact of ELSI research.
Encouraging a robust ELSI portfolio of policy research
As ELSI researchers apply a range of research methods to policy issues, three critical 
questions arise. Each of these questions bears on the potential for ELSI research to achieve a 
high level of rigor and address the needs of policy-makers.
1. How can different research methodologies be leveraged to produce optimal 
approaches for evaluating policy problems?—In anticipating their mandate to 
articulate and disseminate the policy-relevant lessons of their research, ELSI researchers 
have come to appreciate the advantages of interdisciplinary research designs. By themselves, 
purely descriptive studies such as surveys, ethnographies, legal reviews, and conceptual 
taxonomies can provide important data for policy-makers at all levels but they provide little 
guidance on the merits of acting on the data in one way or another. Similarly, strictly 
normative analyses may provide ethical, legal, or clinical frameworks or priorities for 
decision-making, but almost always include uncertainties that require empirical evidence to 
resolve. Moreover, studies using the methods of social science, ethical or legal analysis need 
to be grounded in the lived experience of clinical professionals and their patients. As a 
result, mixed-method studies by collaborative multidisciplinary teams become increasingly 
important. The CEER program was established to help create institutional hubs for such 
teams, but even outside of these Centers, ELSI researchers increasingly find the need to link 
studies to achieve the kind of peripheral vision required for policy translation. To date, the 
major venues for these collaborations have been the ELSI program's various RFA-sponsored 
consortia, and the involvement of ELSI researchers in larger genome science initiatives such 
as the CSER Consortium, eMERGE, the Human Microbiome Project, the Welcome 
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Trust/NIH H3Africa Initiative, and the NBSeq initiative (e.g., 57, 63-66). Each of these 
initiatives involves collaboration among basic, clinical and ELSI research, focused on a 
particular aspect of genome science. The ELSI component of these projects offers a 
powerful opportunity for cross-communication between ELSI and other aspects of genomic 
research. Since these efforts are topic specific, however, by necessity they leave large 
segments of the ELSI research community without natural venues for connection or 
collaboration. The series of NIH-sponsored “ELSI Congress” meetings are one episodic 
response to that need (67), and they have stimulated the creation of a new international on-
line forum for collaboration for ELSI research, the “ELSI 2.0 Collaboratory,” that also seeks 
to provide ELSI researchers with the means to cultivate such teams (68).
As such work moves forward, limitations need to be considered. Efforts to anticipate policy 
problems always have the potential to expend resources on the investigation of undesirable 
effects from genomic technology that never materialize, and thus may be open to charges of 
“catastrophizing.” Looking down the road toward future problems in the application of 
genomics also opens ELSI researchers to the charge of ignoring more proximal decisions in 
the design and implementation of genomic research that might either exacerbate or mitigate 
later problems (69-72). For these reasons, robust interdisciplinary collaboration is necessary 
not only among the empirical, normative and clinical disciplines of ELSI research, but also 
between ELSI researchers and genome scientists. As a new wave of genome and exome 
sequencing studies are showing, working closely with genome scientists, rather than at arm's 
length in advisory or consultancy capacities, can allow ELSI researchers to better target their 
down-stream inquiries and to provide a critical lens on the design and conduct of genomic 
research itself (22,63). Yet collaboration carries with it the potential of co-optation. 
Independent ELSI research can also play an important role in clarifying assumptions, values 
and implications of potential choices at different stages of the translational process. A mix of 
collaboration and communication across disciplinary boundaries is therefore likely to be 
most effective in producing robust policy-relevant findings.
Recommendation # 4
Research teams should explore and funders should promote a broad range of strategies to 
improve interdisciplinary communication and collaboration among ELSI researchers and 
between those disciplines and genome science.
2. How should policy-relevant research be disseminated?—As ELSI research 
addresses these different aspects of the policy-making process, appropriate dissemination of 
research findings is an important consideration. One of the most influential forms of 
dissemination is the contribution that ELSI researchers make to institutional and 
professional practice by collaborating on initiatives with their colleagues in genomic and 
genetic medicine and research. Insights and evidence from ELSI research projects can be 
instrumental to the work of university and hospital committees charged with developing 
responsible interpretations of national guidelines on issues such as genomic data 
management and IRB review, and ongoing relationships between ELSI researchers and 
genome scientists can significantly shape local professional cultures. Other avenues and 
strategies for dissemination are important to consider (and their effectiveness is potentially a 
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topic of ELSI research). Policy briefs and expert testimony are both avenues for 
dissemination. The participation of ELSI researchers on regional and national advisory 
groups addressing a broad range of policy areas, and presentations by ELSI researchers to 
those groups or other policy-making bodies, are also important forms of dissemination. 
Publication in scholarly and scientific journals remains the mainstay for academic 
dissemination, allowing for collaborative development of knowledge across the many 
disciplines involved in ELSI research. However, impact on genomics policy development is 
often greatest if ELSI researchers make their work accessible to policy audiences in venues 
not typically used for their academic scholarship. To conduct their research, ELSI 
researchers become familiar with different professional literatures, languages and formats, 
and often appreciate that their work can have the most direct impact on genomic science if it 
is disseminated in ways atypical for their home departments and disciplines. Thus, junior 
ethics or sociology scholars may be inclined to disseminate their research results to genomic 
or policy audiences, either by publishing in the scientific press or through policy briefs, op-
ed articles in newspapers, press releases, and presentations aimed at the general public, but 
may be advised by their disciplinary elders to keep their “eyes on the prize” of promotion 
and tenure as determined by the traditional standards of their academic homes. More senior 
scholars coming to ELSI research from careers in the humanities, social sciences and law 
may see these forms of dissemination as lying outside their academic responsibilities and 
resist them in the same ways that many bench scientists chafe at mandates to commercialize 
their basic science in the name of “translation.”
To create programmatic contexts in which dissemination efforts more directly targeted to 
policy and scientific audiences will be rewarded and accepted, funders and institutions might 
consider other national efforts to encourage more translational research in the biomedical 
sciences. Just as the NIH Clinical and Translational Science Awards and the institutional 
efforts they have inspired across the country are attempting to change the culture of the basic 
biomedical sciences, incentives are needed to turn the home disciplines of ELSI research in 
a more translational direction. Analogous to the ways in which many academic clinical and 
translational science programs provide core resources to help bench scientists apply and 
commercialize their research through proactive technology transfer services, ELSI 
researchers could benefit from services designed to package their work for scientific, public 
and policy audiences. Presentation methods could include policy briefs, op-ed articles in 
newspapers, press releases, and presentations aimed at the general public. Examples of 
efforts emanating from the current CEERs illustrate the range of possibilities (Table 1), and 
are representative of efforts undertaken by ELSI scholars across a range of institutional 
settings.
Recommendation # 5
Funders should consider mechanisms for the creation of specialized Policy Translation 
Resource Cores accessible by both NIH-funded and independently supported ELSI 
researchers, to help build translational capacity within the research community. These could 
be built on the existing translational components of CEERS, but could also be housed by 
other translational policy centers, national science policy programs (such as the National 
Academy of Sciences), or international ELSI research organizations.
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In considering dissemination, ELSI researchers, like other scientists addressing policy-
relevant questions, need to consider whether they should provide only research information 
and leave policy-makers to draw the policy conclusions, or use their expertise to recommend 
specific policy options (73). There is value to the position of “honest broker” (73), in which 
an expert seeks to help decision-makers consider the pros and cons of different policy 
alternatives, without making a specific recommendation. But there may also be times when 
it is appropriate for an ELSI researcher to take a position about a particular policy choice. 
Normative arguments in favor of or against a particular position on an issue are the expected 
outcomes of many studies in philosophy, bioethics, and law, and multidisciplinary ELSI 
projects typically include such components. For example, many ELSI researchers published 
analyses of the Genetic Information Non-Discrimination Act (GINA) prior to its passage, 
some in favor of the legislation and others raising cautions about this policy approach. (e.g., 
74,75). Of course, all ELSI grantees must comply with relevant rules restricting the use of 
federal funds to support political lobbying. But academic analysis of issues relevant to 
policy is one of the missions of ELSI research, and ELSI researchers are expected to bring 
their normative views and recommendations to their professional roles as members of 
institutional, professional, and federal policy-making advisory committees and initiatives.
On the other hand, our experience suggests that responsible and effective policy 
development is a collective, community process, and requires the participation of multiple 
stakeholders. This means that individual ELSI investigators and projects are rarely equipped 
to promulgate mature policy proposals by themselves, and should not be held to that 
expectation. To be effective in “translating” normative conclusions into policy, ELSI 
researchers need to have access to the appropriate policy-making forums for the phase of the 
process they seek to address.
Recommendation # 6
Like individual genome scientists and scientific teams, ELSI researchers must be allowed 
the academic freedom to draw and report conclusions from their research, whatever 
implications these may have for the current direction or priorities of genome research. 
However, because ELSI research, like science, is a collective enterprise, funders and 
institutions should expect most policy recommendations to be promulgated through 
collaborative consensus mechanisms, often involving established policy forums, rather than 
directly from specific research projects.
3. How should ELSI research be evaluated?—Policies are animated by the interests, 
beliefs, and values of multiple stakeholders, and shaped by the constraints, ideals, and 
priorities of multiple environments. In addition, the policy-making process occurs in 
multiple public and private venues. ELSI research can provide empirical information and 
critical assessments for particular policy-making challenges, but questions remain about how 
the translational mandate of ELSI research should be assessed or evaluated. A starting point 
is to consider who evaluates ELSI research and for what purposes.
ELSI as an academic endeavor—Most ELSI research occurs in academic settings. As a 
matter of course, ELSI researchers are evaluated by academic criteria related to the 
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originality and quality of their work and their recognition among peers. Formal assessment 
occurs in promotion and tenure decisions and contributes to the rigor and stature of ELSI 
research. Academic review is primarily focused on how peers evaluate a scholar's work, and 
does not address dissemination to policy makers. Nor is all ELSI research policy-relevant. 
Just as innovative robust bench science stands on its own merits whether or not it has a 
foreseeable commercial application, excellent work in the humanities, social sciences and 
law can be evaluated independently from its relevance to policy. It would be a mistake to 
compromise the intellectual integrity of these disciplines by diluting their standards of 
scholarly excellence, just as it would be to bring non-scientific criteria into the academic 
evaluation of genome scientists. But it is possible for funders and institutions to help the 
home disciplines and departments of ELSI researchers appreciate the value of policy-
relevance and to build ELSI researchers' capacity to comply with their programmatic 
mandate.
Recommendation # 7
Academic institutions should experiment with creative ways to reward efforts to support 
translational mandates of policy-relevant research, by creating, for example, opportunities 
for leaves of absence to participate more directly in the policy-making process, crediting 
policy-related service activities during promotion and tenure reviews, and encouraging 
expert contributions to policy initiatives within academic communities.
Peer review of grant applications—Review of an applicant's ELSI research grant 
proposal represents another formal evaluation process. Like academic evaluation, this peer 
review process focuses primarily on the quality of the scholarly work proposed, and the 
likelihood that its goals will be accomplished based on the study design and the applicant's 
work to date. This process also includes an evaluation of potential impact, a broader 
question focused on the significance of the work to the field. Given the ELSI program's 
translational mandate, reviewers may be tempted to evaluate grant proposals on their 
promise to influence policy. However, ELSI research encompasses a broad range of 
investigations and methods, not all of it policy relevant. Further, the goal of NIH peer 
review is very specific - to inform the funding agency about the intellectual merits of a 
particular scientific or scholarly research plan, as the basis for the agency's funding 
decisions. Additional programmatic criteria, such as a project's translational promise or 
relevance to the agency's funding priorities, can be applied at different points in the process: 
when funding programs accept applications for review and at subsequent levels of decision-
making about funding priorities. They should not affect an application's peer review priority 
score. This approach acknowledges both the range of ELSI research and the sometimes 
complex relationship that exists between a specific research project and its impact on 
science and health policy, in the same way that the distance between bench and bedside is 
acknowledged in translational genomic research.
Recommendation # 8
When applicants promise to influence policy directly as part of their projects, reviewers may 
legitimately evaluate how they propose to do so. However, different ELSI research studies 
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vary in their policy relevance and potential for policy impact. Explicit discussion of policy 
relevance should therefore not be an a priori expectation in peer review.
Value of the ELSI investment—Neither of these formal evaluation mechanisms fully 
addresses the question of the value to society deriving from investment in policy-related 
ELSI research. There are no simple metrics to accomplish this evaluation, and it necessarily 
involves judgment. Three sources of data are helpful, as academic programs, funding 
agencies, Congress, or the public consider this question. The first is the body of ELSI 
research addressing policy questions, as manifested in publications and reports. One can ask 
whether this body of work addresses the questions and topics currently arising in policy-
making around genomics or has contributed to the identification of previously unrecognized 
questions. Here it is important to note that the NIH can influence the scope of ELSI's policy 
domain through exploratory workshops and Requests for Applications, to ensure that critical 
areas are addressed. A second source of data is citations in policy documents: to what extent 
is ELSI-funded research cited as part of the policy-making process? The third source is the 
contribution of ELSI experts to the policy-making process, in the form of expert testimony; 
policy briefs; and participation on advisory and policy-making bodies. These sources of data 
remain largely untapped, and are themselves useful targets for further ELSI research.
Recommendation # 9
Efforts are needed to document the impact of ELSI research projects on science and health 
policy. Methods of assessing this impact will require input from policymakers, ELSI 
researchers, academic institutions, funding agencies, and the public. Such effort could be 
achieved through funded research, NIH task forces, or other initiatives undertaken by 
funding agencies or professional organizations.
Conclusions
ELSI research offers a range of methodological approaches yielding normative analysis and 
empirical data to inform the policy-making process. This work addresses all phases of the 
policy development process, across a broad range of policy-making venues. In addition, the 
community of ELSI researchers created through the NHGRI ELSI research commitment 
provides expertise as participants in advisory and policy-making bodies, and in expert 
testimony. Our experience in in seeking ways to increase the policy relevance of our work 
through the CEERs has informed both innovative approaches to dissemination (Table 1) and 
the recommendations we present for strengthening the translational impact of ELSI research 
(Table 2).
Deliberate definition of policy-related goals is needed to ensure the appropriate 
dissemination of ELSI research to policy-makers and the public. Creative ways to broaden 
ELSI research dissemination efforts and support collective, collaborative efforts to bring 
ELSI research results to bear on policy issues continue to be needed. Evaluation of ELSI 
research must strike a balance, rewarding both rigor in application of research results to 
policy and broad dissemination, without placing unrealistic expectations on either the 
research or the policy-making process. We hope these recommendations will provide a 
starting point for discussion, aimed ultimately at the creation of consensus-based methods to 
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guide investigators in applying their findings to policy questions and funders and institutions 
in evaluating these critical contributions.
Acknowledgments
Research reported in this publication was supported by the National Human Genome Research Institute of the 
National Institutes of Health under award numbers P50HG003390 (Case Western Reserve University), 
P50HG007257 (Columbia), P50HG003391 (Duke University), P50HG004488 (University of North Carolina), 
P50HG004487 (University of Pennsylvania), and P50HG003374 (University of Washington). The content is solely 
the responsibility of the authors and does not necessarily represent the official views of the National Institutes of 
Health or the authors' affiliated institutions.
References
1. Juengst ET. Self-critical federal science? The ethics experiment within the U.S. Human Genome 
Project. Soc Philos Policy. 1996 Summer;13(2):63–95. Department of Health and Human Services 
RFA-HG-12-005 Specialized Centers of Excellence in ELSI Research (CEER) (P50). http://
grants.nih.gov/grants/guide/rfa-files/RFA-HG-12-005.html. [PubMed: 11653300] 
2. Hanna, KE. The Ethical Legal and Social Implications Program of the National Center for Human 
Genome Research: A Missed Opportunity?. In: Bulger, R.; Bobby, E.; Fineberg, H., editors. 
Society's Choices: Social and Ethical Decision-making in Biomedicine. Washington, DC: National 
Academies Press; 1995. p. 432-58.
3. De Leeuw, E. Policies for Health The effectiveness of their development, adoption, and 
implementation. In: McQueen, D.; Jones, CM., editors. Global Perspectives on Health Promotion 
Effectiveness. Springer; New York: 2007. p. 51-66.Chapter 5
4. Genetic Information Nondiscrimination Act (GINA). [Accessed March 15, 2014] http://
www.gpo.gov/fdsys/pkg/PLAW-110publ233/content-detail.html
5. US Department of Health and Human Services. [Accessed March 15, 2014] Federal Policy for the 
Protection of Human Subjects (‘Common Rule’). http://www.hhs.gov/ohrp/humansubjects/
commonrule/
6. National Institutes of Health Data Sharing Policies. [Accessed March 15, 2014] NIH Data Sharing 
Policy and Implementation Guidance. available at https://grants.nih.gov/grants/policy/data_sharing/
data_sharing_guidance.htm
7. Clinical Laboratory Improvement Amendments (CLIA). [Accessed March 15, 2014] http://
www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html?redirect=/clia/
8. US Food and Drug Administration (FDA). [Accessed March 15, 2014] http://www.fda.gov
9. Evaluation of Genomic Applications in Practice and Prevention (EGAPP). [Accessed March 15, 
2014] http://www.egappreviews.org/
10. US Preventive Services Task Force. [Accessed March 15, 2014] Genetic Risk Assessment and 
BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility. http://
www.uspreventiveservicestaskforce.org/uspstf/uspsbrgen.htm
11. [Accessed March 15, 2014] American College of Medical Genetics and Genomics Practice 
Guidelines. https://www.acmg.net/ACMG/Publications/Practice_Guidelines/ACMG/Publications/
Practice_Guidelines.aspx
12. American College of Obstetrics and Gynecology. [Accessed March 15, 2014] http://www.acog.org
13. American Society of Human Genetics Policy and Position Statement Archive. [Accessed March 
15, 2014] http://www.ashg.org/pages/policy_statements.shtml
14. American Academy of Pediatrics Committee on Genetics. [Accessed March 15, 2014] http://
www2.aap.org/visit/cmte18.htm
15. American Medical Association. [Accessed March 15, 2014] Cystic Fibrosis Testing. http://
www.ama-assn.org/ama/pub/physician-resources/medical-science/genetics-molecular-medicine/
related-policy-topics/genetic-testing/cystic-fibrosis-testing.page?
16. Beskow LM, Botkin JR, Daly M, Juengst ET, Lehmann LS, Merz JF, Pentz R, Press NA, Ross LF, 
Sugarman J, Susswein LR, Terry SF, Austin MA, Burke W. Ethical issues in identifying and 
Burke et al. Page 12






















recruiting participants for familial genetic research. Am J Med Genet A. 2004 Nov 1; 130A(4):
424–31. [PubMed: 15455364] 
17. Clayton EW, Steinberg KK, Khoury MJ, Thomson E, Andrews L, Kahn MJ, Kopelman LM, Weiss 
JO. Informed consent for genetic research on stored tissue samples. JAMA. 1995 Dec 13; 274(22):
1786–92. [PubMed: 7500511] 
18. Henderson GE, Edwards TP, Cadigan RJ, Davis AM, Zimmer C, Conlon I, Weiner BJ. 
Stewardship practices of U.S. biobanks. Sci Transl Med. 2013 Dec 11.5(215):215cm7.10.1126/
scitranslmed.3007362 [PubMed: 24337477] 
19. Dressler LG, Smolek S, Ponsaran R, Markey JM, Starks H, Gerson N, Lewis S, Press N, Juengst E, 
Wiesner GL. GRRIP Consortium. IRB perspectives on the return of individual results from 
genomic research. Genet Med. 2012 Feb; 14(2):215–22. [PubMed: 22241094] 
20. Olson, S.; Berger, A. Roundtable on Translating Genomic-Based Research for Health. National 
Academies Press; 2012. Genome-Based Diagnostics: Clarifying Pathways to Clinical Use -
Workshop Summary. 
21. National Human Genome Research Institute. [Accessed March 15, 2014] Clinical Sequencing 
Exploratory Research (CSER). http://www.genome.gov/27546194
22. Nelkin, D.; Lindee, MS. The DNA Mystique: the Gene as Cultural Icon. New York: WH Freeman; 
1995. 
23. Merriam-Webster Policy. [Accessed March 15, 2014] http://www.merriam-webster.com/
dictionary/policy
24. Cook-Deegan R, Heaney C. Patents in genomics and human genetics. Annu Rev Genomics. Hum 
Genet. 2010 Sep 22.11:383–425.
25. National Institutes of Health Data Sharing Policies. [Accessed March 15, 2014] Policy for Sharing 
of Data Obtained from NIH Supported or Conducted Genome-Wide Association Studies (GWAS). 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html
26. Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP. Simplifying informed consent for 
biorepositories: stakeholder perspectives. Genet Med. 2010 Sep; 12(9):567–72. [PubMed: 
20697289] 
27. McGuire AL, Oliver JM, Slashinski MJ, Graves JL, Wang T, Kelly PA, Fisher W, Lau CC, Goss J, 
Okcu M, Treadwell-Deering D, Goldman AM, Noebels JL, Hilsenbeck SG. To share or not to 
share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 
13(11):948–55. [PubMed: 21785360] 
28. Harding A, Harper B, Stone D, O'Neill C, Berger P, Harris S, Donatuto J. Conducting research 
with tribal communities: sovereignty, ethics, and data-sharing issues. Environ Health Perspect. 
2012 Jan; 120(1):6–10. [PubMed: 21890450] 
29. Cook-Deegan R, Conley JM, Evans JP, Vorhaus D. The next controversy in genetic testing: 
clinical data as trade secrets? Eur J Hum Genet. 2013 Jun; 21(6):585–8. [PubMed: 23150081] 
30. US Department of Health and Human Services. [Accessed March 15, 2014] Health Information 
Privacy. http://www.hhs.gov/ocr/privacy/
31. Blumenthal D, Campbell EG, Gokhale M, Yucel R, Clarridge B, Hilgartner S, Holtzman NA. Data 
withholding in genetics and the other life sciences: prevalences and predictors. Acad Med. 2006 
Feb; 81(2):137–45. [PubMed: 16436574] 
32. Kaye J, Heeney C, Hawkins N, de Vries J, Boddington P. Data sharing in genomics--re-shaping 
scientific practice. Nat Rev Genet. 2009 May; 10(5):331–5. [PubMed: 19308065] 
33. Fullerton SM, Anderson NR, Guzauskas G, Freeman D, Fryer-Edwards K. Meeting the governance 
challenges of next-generation biorepository research. Sci Transl Med. 2010 Jan 20.2(15):
15cm3.10.1126/scitranslmed.3000361
34. Joly Y, Dove ES, Knoppers BM, Bobrow M, Chalmers D. Data sharing in the post-genomic world: 
the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance 
Office (DACO). PLoS Comput Biol. 2012; 8(7):e1002549.10.1371/journal.pcbi.1002549 
[PubMed: 22807659] 
35. Hull SC, Sharp RR, Botkin JR, Brown M, Hughes M, Sugarman J, Schwinn D, Sankar P, Bolcic-
Jankovic D, Clarridge BR, Wilfond BS. Patients' views on identifiability of samples and informed 
consent for genetic research. Am J Bioeth. 2008 Oct; 8(10):62–70. [PubMed: 19003716] 
Burke et al. Page 13






















36. Lemke AA, Smith ME, Wolf WA, Trinidad SB. GRRIP Consortium. Broad data sharing in genetic 
research: views of institutional review board professionals. IRB. 2011 May-Jun;33(3):1–5. 
[PubMed: 21736136] 
37. Kaufman DJ, Murphy-Bollinger J, Scott J, Hudson KL. Public opinion about the importance of 
privacy in biobank research. Am J Hum Genet. 2009 Nov; 85(5):643–54. [PubMed: 19878915] 
38. Trinidad SB, Fullerton SM, Bares JM, Jarvik GP, Larson EB, Burke W. Genomic research and 
wide data sharing: views of prospective participants. Genet Med. 2010 Aug; 12(8):486–95. 
[PubMed: 20535021] 
39. Kaufman D, Bollinger J, Dvoskin R, Scott J. Preferences for opt-in and opt-out enrollment and 
consent models in biobank research: a national survey of Veterans Administration patients. Genet 
Med. 2012 Sep; 14(9):787–94. [PubMed: 22538255] 
40. Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, Gaines AD, 
Juengst ET, Karlinsky H, Miles S, Murray TH, Quaid KA, Relkin NR, Roses AD, George-Hyslop 
PH, Sachs GA, Steinbock B, Truschke EF, Zinn AB. The clinical introduction of genetic testing 
for Alzheimer disease. An ethical perspective. JAMA. 1997 Mar 12; 277(10):832–6. [PubMed: 
9052715] 
41. Asch DA, Hershey JC, Dekay ML, Pauly MV, Patton JP, Jedrziewski MK, Frei F, Giardine R, 
Kant JA, Mennuti MT. Carrier screening for cystic fibrosis: costs and clinical outcomes. Med 
Decis Making. 1998 Apr-Jun;18(2):202–12. [PubMed: 9566453] 
42. Geller G, Botkin JR, Green MJ, Press N, Biesecker BB, Wilfond B, Grana G, Daly MB, Schneider 
K, Kahn MJ. Genetic testing for susceptibility to adult-onset cancer. The process and content of 
informed consent. JAMA. 1997 May 14; 277(18):1467–74. [PubMed: 9145720] 
43. Parens E, Asch A. The disability rights critique of prenatal genetic testing. Reflections and 
Recommendations. Hastings Cent Rep. 1999 Sep-Oct;29(5):S1–22. [PubMed: 10587809] 
44. Lindor NM, Peterson GM, Hadley DW, Kinney AY, Miesfeldt S, Lu K, Lynch P, Burke W, Press 
N. Recommendations for the care of individuals with an inherited predisposition to cancer: Lynch 
Syndrome (Hereditary Nonpolyposis Colorectal Cancer). JAMA. 2006; 296:15–7. 17.
45. McGowan ML, Fishman JR, Lambrix MA. Personal genomics and individual identities: 
motivations and moral imperatives of early users. New Genet Soc. 2010 Sep 1; 29(3):261–290. 
[PubMed: 21076647] 
46. Rothwell E, Anderson RA, Swoboda KJ, Stark L, Botkin JR. Public attitudes regarding a pilot 
study of newborn screening for spinal muscular atrophy. Am J Med Genet A. 2013 Apr; 161A(4):
679–86. [PubMed: 23443997] 
47. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, 
O'Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG. ACMG 
recommendations for reporting of incidental findings in clinical exome and genome sequencing. 
Genet Med. 2013 Jul; 15(7):565–74. [PubMed: 23788249] 
48. Allyse M, Michie M. Not-so-incidental findings: the ACMG recommendations on the reporting of 
incidental findings in clinical whole genome and whole exome sequencing. Trends Biotechnol. 
2013 Aug; 31(8):439–41. [PubMed: 23664778] 
49. Biesecker LG. Incidental variants are critical for genomics. Am J Hum Genet. 2013 May 2; 92(5):
648–51. [PubMed: 23643378] 
50. Burke W, Matheny Antommaria AH, Bennett R, Botkin J, Clayton EW, Henderson GE, Holm IA, 
Jarvik GP, Khoury MJ, Knoppers BM, Press NA, Ross LF, Rothstein MA, Saal H, Uhlmann WR, 
Wilfond B, Wolf SM, Zimmern R. Recommendations for returning genomic incidental findings? 
We need to talk! Genet Med. 2013 Nov; 15(11):854–9. [PubMed: 23907645] 
51. Green RC, Lupski JR, Biesecker LG. Reporting genomic sequencing results to ordering clinicians: 
incidental, but not exceptional. JAMA. 2013 Jul 24; 310(4):365–6. [PubMed: 23917280] 
52. Ross LF, Rothstein MA, Clayton EW. Mandatory extended searches in all genome sequencing: 
“incidental findings,” patient autonomy, and shared decision making. JAMA. 2013 Jul 24; 310(4):
367–8. [PubMed: 23917281] 
53. Wolf SM, Annas GJ, Elias S. Point-counterpoint. Patient autonomy and incidental findings in 
clinical genomics. Science. 2013 May 31; 340(6136):1049–50. [PubMed: 23686341] 
Burke et al. Page 14






















54. Klitzman R, Appelbaum PS, Fyer A, Martinez J, Buquez B, Wynn J, Waldman CR, Phelan J, 
Parens E, Chung WK. Researchers' views on return of incidental genomic research results: 
qualitative and quantitative findings. Genet Med. 2013; 15(11):888–895. [PubMed: 23807616] 
55. McGuire AL, Joffe S, Koenig BA, Biesecker BB, McCullough LB, Blumenthal-Barby JS, 
Caulfield T, Terry SF, Green RC. Point-counterpoint. Ethics and genomic incidental findings. 
Science. 2013 May 31; 340(6136):1047–8. [PubMed: 23686340] 
56. Clayton EW, McCullough LB, Biesecker LG, Joffe S, Ross LF, Wolf SM. For The Clinical 
Sequencing Exploratory Research CSER Consortium Pediatrics Working Group. Addressing the 
ethical challenges in genetic testing and sequencing of children. Am J Bioeth. 2014 Mar; 14(3):3–
9. [PubMed: 24592828] 
57. [Accessed March 15, 2014] Presidential Commission for the Study of Bioethical Issues. http://
www.bioethics.gov
58. Institute of Medicine Roundtable on Translating Genomic-Based Research for Health. [Accessed 
March 15, 2014] http://www.iom.edu/Activities/Research/GenomicBasedResearch.aspx
59. National Institutes of Health Office of Science Policy. [Accessed March 15, 2014] Secretary's 
Advisory Committee on Genetic Testing. http://osp.od.nih.gov/secretarys-advisory-committee-
genetic-testing/conference/sacgt-1
60. National Institutes of Health Office of Science Policy. [Accessed March 15, 2014] Secretary's 
Advisory Committee on Genetics, Health and Society. http://osp.od.nih.gov/office-clinical-
research-and-bioethics-policy/genetics-health-and-society/sacghs-archives
61. Yesley M. What's ELSI got to do with it? Bioethics and the Human Genome Project. New 
Genetics and Society. 2008; 27(1):1–6.
62. Clayton EW, Smith M, Fullerton SM, Burke W, McCarty CA, Koenig BA, McGuire AL, Beskow 
LM, Dressler L, Lemke AA, Ramos EM, Rodriguez LL. Consent and Community Consultation 
Working Group of the eMERGE Consortium. Confronting real time ethical, legal, and social 
issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genet Med. 2010 
Oct; 12(10):616–20. [PubMed: 20733502] 
63. McGuire AL, Colgrove J, Whitney SN, Diaz CM, Bustillos D, Versalovic J. Ethical, legal, and 
social considerations in conducting the Human Microbiome Project. Genome Res. 2008 Dec; 
18(12):1861–4. [PubMed: 18971311] 
64. Wright GE, Koornhof PG, Adeyemo AA, Tiffin N. Ethical and legal implications of whole genome 
and whole exome sequencing in African populations. BMC Med Ethics. 2013 May 28.14:21. 
[PubMed: 23714101] 
65. National Institutes of Health. [Accessed March 15, 2014] NIH program explores the use of 
genomic sequencing in newborn healthcare. http://www.nih.gov/news/health/sep2013/
nhgri-04.htm
66. Henderson GE, Juengst ET, King NM, Kuczynski K, Michie M. What research ethics should learn 
from genomics and society research: lessons from the ELSI Congress of 2011. J Law Med Ethics. 
2012 Winter;40(4):1008–24. [PubMed: 23289702] 
67. Kaye J, Meslin EM, Knoppers BM, Juengst ET, Deschênes M, Cambon-Thomsen A, Chalmers D, 
De Vries J, Edwards K, Hoppe N, Kent A, Adebamowo C, Marshall P, Kato K. Research 
priorities. ELSI 2.0 for genomics and society. Science. 2012 May 11; 336(6082):673–4. [PubMed: 
22582247] 
68. Fisher E. Lessons learned from the Ethical, Legal and Social Implications Program (ELSI): 
Planning societal implications research for the National Nanotechnology Program. Technology in 
Society. 2005; 27:321–328.
69. Rabinow P, Bennett G. Synthetic biology: ethical ramifications. Systems and Synthetic Biology. 
2009; 3:99–108. [PubMed: 19816805] 
70. Rabinow; Bennet, G. Designing Human Practices: An Experiment with Synthetic Biology. 
Chicago: University of Chicago Press; 2012. 
71. Balmer AS, Bulpin KJ. Left to their own devices: post-ELSI ethical equipment and the iGEM 
competition. BioSocieties. 2013; 8(3):311–335. [PubMed: 24159360] 
72. Pielke, RA. The Honest Broker: Making Sense of Science in Policy and Politics. Cambridge: 
Cambridge University Press; 2007. 
Burke et al. Page 15






















73. Hudson KL. Prohibiting genetic discrimination. N Engl J Med. 2007 May 17; 356(20):2021–3. 
[PubMed: 17507700] 
74. Rothstein MA. Is GINA worth the wait? J Law Med Ethics. 2008 Spring;36(1):174–8. [PubMed: 
18315769] 
Burke et al. Page 16























Contributions of ELSI research at different phases of the policy-making process.
Burke et al. Page 17











































Burke et al. Page 18
Table 1
Examples of Dissemination of Policy-Relevant Documents by CEERs
CEER Topic Area Example
Center for Genetic 




Ethical and legal issues related 
to newborn screening
Testimony to the Ethics and Legal Workgroup for the National Newborn 
Screening Translational Research Network (Aaron Goldenberg PhD, MPH).
Center for Research on 
Ethical, Legal & Social 
Implications of 
Psychiatric, Neurologic & 
Behavioral Genetics, 
Columbia University
Return of incidental findings 
from genomic research
Testimony to the Presidential Commission for the Study of Bioethical Issues 
(Erik Parens, PhD). Available on the web (http://bioethics.gov/node/2783).
Center for Public 
Genomics, Duke 
University
The risks and benefits of 
intellectual property 
protections in genomics, 
including ethical, legal and 
social issues related to the 
patenting of DNA
Presentations by Duke CEER investigators (Robert Cook-Deegan, PHD and 
Arti Rai, JD) and former Duke CEER post-doctoral fellow (Sapna Kumar, now 
at the University of Houston School of Law) at the US Patent & Trademark 
Office roundtable on genetic testing diagnostic verification. Available on the 
web (http://www.genome.duke.edu/centers/cpg/cpg-contributions-BRCA/)
Center for Genomics and 
Society (CGS), University 
of North Carolina at 
Chapel Hill
Best practices, governance 
models, and ethical issues in 
biobanking research, including 
data sharing, sample 
ownership, broad consent, and 
confidentiality.
CGS investigator service on policy committees at local (UNC Committee on 
Tissue Banks and DNA Repositories), national (NCI “Best Practices for 
Biospecimen Research”, http://biospecimens.cancer.gov/practices/; NIH Cancer 
Genome Atlas Project “Human Subjects Protection and Data Access Policy”, 
http://cancergenome.nih.gov/PublishedContent/Files/pdfs/TCGA%20Human
%20Subjects%20Protection%20and%20Data%20Access%20Policies
%20Rev_2014-01-16.pdf) and international levels (International Cancer 
Genome Consortium “Informed Consent and Ethical Oversight Guidelines”. 
http://icgc.org/icgc/goals-structure-policies-guidelines/e1-informed-consent-
access-and-ethical-oversight).
Center for Genomics and 
Healthcare Equality 
(CGHE), University of 
Washington
Ethical conduct of research 
involving American Indian and 
Alaska Native participants
Report of a collaborative workshop summarizing perspectives, illustrative 
scenarios, resources and take home points for effective research collaboration 
between universities and tribal organizations. Available on the web (https://
dl.dropboxusercontent.com/u/1711621/TUIREW%20final%20report.pdf) and 
disseminated in hard copy to CGHE regional partners.
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Table 2
Summary of Recommendations
1 The translational mandate for ELSI research should be interpreted expansively, to include governmental and professional policy but also 
the broader social, economic, and cultural influences that shape public reception and use of genomic information.
2 ELSI research is uniquely positioned to assemble and assess the interaction of policies occurring under the broad definitional rubric laid out 
in this paper. Because few single research projects can span the whole spectrum of relevant policy spheres, opportunities should be sought 
or where possible created to pursue policy-relevant ELSI research through collaborations between studies addressing different levels of 
policy-making, rather than by individual research projects attempting to extrapolate policy implications in isolation.
3 The full interdisciplinary range of ELSI research at the stages of policy issue identification, policy option development, and policy impact 
assessment should be considered forms of translational ELSI research. The contributions that individual ELSI researchers make to policy 
initiatives cannot be easily separated from the research programs these individuals direct and should be considered evidence of the 
translational impact of ELSI research.
4 Research teams should explore and funders should promote a broad range of strategies to improve interdisciplinary communication and 
collaboration among ELSI researchers and between those disciplines and genome science.
5 Funders should consider mechanisms for the creation of specialized Policy Translation Resource Cores accessible by both NIH-funded and 
independently supported ELSI researchers, to help build translational capacity within the research community. These could be built on the 
existing translational components of CEERS, but could also be housed by other translational policy centers, national science policy 
programs (such as the National Academy of Sciences), or international ELSI research organizations.
6 Like individual genome scientists and scientific teams, ELSI researchers must be allowed the academic freedom to draw and report 
conclusions from their research, whatever implications these may have for the current direction or priorities of genome research. However, 
because ELSI research, like science, is a collective enterprise, funders and institutions should expect most policy recommendations to be 
promulgated through collaborative consensus mechanisms, often involving established policy forums, rather than directly from specific 
research projects.
7 Academic institutions should experiment with creative ways to reward efforts to support translational mandates of policy-relevant research, 
by creating, for example, opportunities for leaves of absence to participate more directly in the policy-making process, crediting policy-
related service activities during promotion and tenure reviews, and encouraging expert contributions to policy initiatives within academic 
communities.
8 When applicants promise to influence policy directly as part of their projects, reviewers may legitimately evaluate how they propose to do 
so. However, different ELSI research studies vary in their policy relevance and potential for policy impact. Explicit discussion of policy 
relevance should therefore not be an a priori expectation in peer review.
9 Efforts are needed to document the impact of ELSI research projects on science and health policy. Methods of assessing this impact will 
require input from policymakers, ELSI researchers, academic institutions, funding agencies, and the public. Such efforts could be achieved 
through funded research, NIH task forces, or other initiatives undertaken by funding agencies or professional organizations.
Genet Med. Author manuscript; available in PMC 2015 July 01.
